SS Innovations Submits FDA Response for SSi Mantra 510(k) — Review Expected Q1 2027
SSII is trading near its 52-week low of $2.5 (2.0% above the low).
Summary
SS Innovations submitted its FDA response for the SSi Mantra 510(k) on October 5, 2026, including final clinical and bridging study data. FDA review is expected to complete in Q1 2027.
Key Events · Product Development and Regulatory · SSII
-
FDA Response Submitted
On October 5, 2026, the company submitted its response to the FDA's request for additional information (AINN) for the SSi Mantra 510(k) application.
-
Clinical Data Included
The response includes final data from an expanded human clinical and human factors validation study and a bridging study completed in August 2026 at Hospital Internacional de Colombia.
-
FDA Review Timeline
The company anticipates the FDA will complete its review of the AINN response and 510(k) submission in the first quarter of 2027.
-
Consultant Engaged
Daniel & Daniel Consulting, LLC was engaged to assist with the AINN response, studies, and 510(k) submission for the initial cholecystectomy indication.
Analysis · SSII · Industrial Applications And Services
SS Innovations has submitted its response to the FDA's request for additional information on the SSi Mantra surgical robotic system's 510(k) application. The response includes final data from an expanded human clinical and human factors validation study plus a bridging study completed in Colombia. This is a critical regulatory milestone for the company's flagship product — FDA clearance would open the U.S. market, the largest surgical robotics market globally. The company expects FDA review to complete in Q1 2027. Against a backdrop of going-concern warnings, material weaknesses, and a recent $20M convertible note with variable-price conversion, this regulatory progress is a meaningful positive development, though the timeline remains uncertain and the company's financial position is fragile.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SSII was trading at $2.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $511.2M. The 52-week trading range was $2.50 to $10.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.